Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yong Park

Neurology with Special Qualifications in Child Neurology Augusta, GA Medical Doctor

NPI 1760582712 CMS profile 307459

1120 15Th Street, Augusta, GA 30912

Open in the dashboard

General payments

$77,884

681 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$315,202 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Yong Park of Augusta, GA is reported in the CMS Open Payments database as having received $77,884 across 681 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $315,202 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,914 72
2024 General $10,716 98
2023 General $7,007 90
2022 General $5,824 87
2021 General $11,399 100
2020 General $3,915 95
2019 General $28,109 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yong Park
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Yong Park were reported at $10,914. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Yong Park Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $28,109 $262 $68–$1,313 $163
2020 $3,915 $188 $46–$1,222 $114
2021 $11,399 $183 $45–$1,356 $132
2022 $5,824 $229 $72–$1,177 $149
2023 $7,007 $269 $93–$1,195 $160
2024 $10,716 $300 $98–$1,428 $164
2025 $10,914 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Greenwich Biosciences, Inc. $39,156 86 payments
  2. Jazz Pharmaceuticals Inc. $27,109 66 payments
  3. UCB, Inc. $2,341 97 payments
  4. SK Life Science, Inc. $1,417 52 payments
  5. Neurelis, Inc. $1,351 54 payments
  6. Sunovion Pharmaceuticals Inc. $948 84 payments
  7. Supernus Pharmaceuticals, Inc. $713 50 payments
  8. Eisai Inc. $692 23 payments
  9. Harmony Biosciences LLC $593 23 payments
  10. Catalyst Pharmaceuticals, Inc. $583 30 payments
  11. Other $2,980 116 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,904 22 payments
  2. Food and Beverage $14,965 630 payments
  3. Travel and Lodging $6,453 26 payments
  4. Consulting Fee $500 1 payment
  5. Education $62 2 payments
Products named General payments · program years 2019–2025
  1. Epidiolex $65,954 145 payments
  2. Briviact $1,393 62 payments
  3. VALTOCO $1,351 54 payments
  4. APTIOM $1,044 88 payments
  5. Fycompa Neurology $692 23 payments
  6. FYCOMPA Neurology $583 30 payments
  7. Fintepla $567 25 payments
  8. Wakix $404 16 payments
  9. OXTELLAR XR $389 28 payments
  10. XYWAV $312 7 payments
  11. Other $3,783 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

458

Median for Neurology: 833

Drug cost

$435,809

Median for Neurology: $202,670

Branded share of claims

33.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 44 $303,859
Xcopri Cenobamate Brand 30 $32,950
Fycompa Perampanel Brand 27 $23,813
Nayzilam Midazolam Brand 28 $22,301
Topamax Topiramate Brand 12 $18,831
Keppra Levetiracetam Brand 12 $11,976
Oxcarbazepine Generic 54 $10,450
Clobazam Generic 31 $3,212
Lacosamide Generic 32 $2,822
Levetiracetam Generic 56 $2,544

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$3,321

Medicare's payments for the services billed

Medicare patients

54

Average age 63

Services billed

67

24 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Ischemic heart disease 37%
Diabetes 31%
Depression 31%
Arthritis 30%
Chronic kidney disease 28%
Alzheimer's or dementia 28%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $8,686
$8,686 44 —
VALTOCO
  • Neurelis, Inc. $357
$357 — —
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $253
$253 27 —
Briviact
  • UCB, Inc. $212
$212 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

681 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record